Trial Profile
Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Antithymocyte globulin; Busulfan; Busulfan; Methotrexate; Tacrolimus; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Jul 2022 Results published in the Transplantation and Cellular Therapy
- 18 Mar 2021 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 Planned End Date changed from 11 Mar 2020 to 5 Mar 2021.